Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs

- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation, single-antigen phage SNS-301 program upon analysis of clinical activity and antigen specific T-cell data - -

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two  longstanding (8 and 10 months) stable diseases observed in patients with no response to prior  PD-1 blockade – – Data show

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and neck accepted for presentation at ASCO 2021 -     - Patient dosing underway in second cohort of

Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board

BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a  clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D.,

Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors

Entrepreneurial leader brings expertise growing biotech platform companies  BOSTON and ROCKVILLE, Md. , April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for

Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

 -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cell

Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index

BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000® Index

Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

BOSTON and ROCKVILLE, Md. , March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi , President and Chief Executive Officer of

Sensei Biotherapeutics Announces Closing of Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052

Displaying 1 - 10 of 13